Impact of branched-chain amino acids and frailty on the management of lenvatinib-related fatigue in patients with hepatocellular carcinoma

Clin Mol Hepatol. 2021 Oct;27(4):616-619. doi: 10.3350/cmh.2021.0258. Epub 2021 Sep 13.

Authors

Shigeo Shimose¹, Shunji Koya², Takumi Kawaguchi¹, Keisuke Hirota², Sachiyo Yoshio³, Takashi Niizeki¹, Hiroo Matsuse^{2

4}, Takuji Torimura¹

Affiliations

¹ Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan.
² Division of Rehabilitation, Kurume University Hospital, Kurume, Japan.
³ Department of Liver Disease, Research Center for Hepatitis and Immunology, National Center for Global Health and Medicine, Kohnodai, Japan.
⁴ Department of Orthopedics, School of Medicine, Kurume University, Kurume, Japan.

No abstract available

Keywords: Amino acids, Branched-chain; Carcinoma, Hepatocellular; Fatigue; Frailty; Lenvatinib.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Amino Acids, Branched-Chain / therapeutic use
Antineoplastic Agents* / adverse effects
Carcinoma, Hepatocellular* / complications
Carcinoma, Hepatocellular* / drug therapy
Fatigue / etiology
Frailty*
Humans
Liver Neoplasms* / complications
Liver Neoplasms* / drug therapy
Phenylurea Compounds / adverse effects
Quinolines

Substances

Amino Acids, Branched-Chain
Antineoplastic Agents
Phenylurea Compounds
Quinolines
lenvatinib

Grants and funding